Ziel der Studie: To evaluate the maximum tolerated dose (MTD) of choline salicylate (CS) that can be combined with selinexor twice weekly in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) or mantle cell lymphoma (MCL). (Primary)

Projektleiter:  Jonas Paludo, M.D., Mayo Clinic in Rochester, Minnesota, United States

Kontaktdaten: Clinical Trials Referral Office   Phone: +1-855-776-0015   Email: mayocliniccancerstudies@mayo.edu  

Gewünschte Einbeziehung des Patienten: 18 Years and older 

ClinicalTrials.gov-Kennung: NCT04640779